Diabetes Pill Burns Fat, Protects Muscle & Appetite
- A novel oral medication is demonstrating potential in managing type 2 diabetes and obesity by enhancing fat burning and regulating blood sugar levels, without the common side effects...
- Researchers at Karolinska Institutet and Stockholm University have published a study in Cell detailing the positive effects of a new drug candidate in preclinical trials.
- The drug aims to increase fat burning and improve blood sugar control without causing appetite suppression or muscle loss - common drawbacks of current medications.
“`html
New Drug Shows Promise for Type 2 Diabetes and Obesity Treatment
Table of Contents
A novel oral medication is demonstrating potential in managing type 2 diabetes and obesity by enhancing fat burning and regulating blood sugar levels, without the common side effects associated with existing treatments.
Key Findings and Mechanism of Action
Researchers at Karolinska Institutet and Stockholm University have published a study in Cell detailing the positive effects of a new drug candidate in preclinical trials. The treatment, administered as a tablet, operates thru a distinct mechanism compared to popular GLP-1 receptor agonists like Ozempic, which require injections. Unlike GLP-1 drugs that primarily target appetite regulation via gut-brain signaling, this new approach focuses on metabolic processes.
The drug aims to increase fat burning and improve blood sugar control without causing appetite suppression or muscle loss – common drawbacks of current medications. This is achieved by modulating a different biological pathway, offering a possibly more favorable side effect profile. The study suggests the drug impacts how the body utilizes energy, shifting it towards fat metabolism.
Clinical Trial Plans and Collaboration
Atrogi AB, the company spearheading the drug’s development, is planning a Phase II clinical trial to assess whether the promising results observed in earlier research translate to individuals with type 2 diabetes or obesity. This trial represents a meaningful step towards potential clinical request.
The research is a collaborative effort involving Professor Volker M. Lauschke and teams from several prestigious institutions: Karolinska Institutet, Stockholm University, Uppsala University, the University of Copenhagen, Monash University, and the University of Queensland. funding for the project has been secured from the Swedish Research Council, the Swedish society for Medical Research, the Novo Nordisk Foundation, and other sources.
Financial Disclosures and Potential Conflicts of Interest
Transparency regarding financial interests is crucial. Several authors of the study are either employed by or hold shares in Atrogi AB, the company funding the clinical trial. Tore Bengtsson, founder and chief scientific officer of Atrogi AB, is a key figure in the drug’s development and, along with a co-author, has filed patent applications related to the studied substances. Detailed facts regarding these affiliations is available in the full publication.